LINC02625: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02625

NCBI ID: G107984237

LINC02625

Other Name(s): long intergenic non-protein coding RNA 2625 | Long intergenic non-protein coding RNA 2625, transcript variant X4 | LINC02625 variant X4

LINC02625: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02625 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, length, and composition, which has caught the attention of researchers due to its potential role in various biological processes. LINC02625 is a good candidate for drug targeting or biomarker discovery due to its unique properties and the involvement of various cellular pathways.

Structure and Function

LINC02625 is a transcribed RNA molecule that is longer than 200 nucleotides. It has a unique 5'-end that is defined by a conserved core sequence of 136 nucleotides. The 3'-end of the RNA is a highly conserved stem-loop region that is responsible for the formation of a stable double helix.

The primary function of LINC02625 is not well understood, but it is involved in various cellular processes, including cell growth, apoptosis, and inflammation. LINC02625 has been shown to be involved in the regulation of cell adhesion, migration, and the cytoskeleton. It has also been implicated in the regulation of gene expression, DNA replication, and chromatin remodeling.

As a drug target, LINC02625 could be targeted with small molecules or antibodies that interfere with its function. For example, LINC02625 has been shown to play a role in the regulation of T cell development and function. Therefore, small molecules that specifically target LINC02625 could be developed as potential therapeutic agents for T cell-related diseases.

As a biomarker, LINC02625 could be used to diagnose and monitor various diseases. For example, LINC02625 has been shown to be involved in the regulation of cell death, which could be used as a biomarker for cancer, neurodegenerative diseases, and other conditions that involve cell death.

Expression and regulation

LINC02625 is highly expressed in various tissues and cells, including brain, pancreas, and heart. It has been shown to be involved in the regulation of gene expression, and its expression levels can be modulated by various factors, including growth factors, chemokines, and stress factors.

The regulation of LINC02625 expression is complex and involves multiple mechanisms. One of the known mechanisms involves the binding of LINC02625 to the RNA polymerase II (RNA polymerase II) complex. This interaction between LINC02625 and RNA polymerase II allows the RNA polymerase II to specifically target the LINC02625 gene for transcription.

Another mechanism of LINC02625 regulation involves the binding of LINC02625 to the microRNA (miRNA) system. miRNA are small non-coding RNAs that play a role in post-transcriptional gene regulation by binding to specific mRNAs. LINC02625 has been shown to interact with several miRNAs, including miR-18a, miR-30a, and miR-202. These interactions between LINC02625 and miRNAs may regulate the translation and stability of LINC02625 RNA, which could have implications for its function in cellular processes.

LINC02625 function in diseases

The function of LINC02625 in diseases is still being explored, but its involvement in various cellular processes suggests that it may be involved in the development and progression of various diseases.

One potential disease that may be related to LINC02625 is cancer. LINC02625 has been shown to be involved in the regulation of cell apoptosis, which is a

Protein Name: Long Intergenic Non-protein Coding RNA 2625

The "LINC02625 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02625 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets